Company Overview and News

Carpentaria Exploration to lift cash position as it eyes production

Carpentaria Exploration Ltd (ASX:CAP) is an emerging producer from the Hawsons Iron Project in eastern Australia, which is targeting a 10 million tonne per annum production of Hawsons Supergrade® iron product.

Aton Strengthens Management and Exploration Team

2016-10-17 marketwired
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 17, 2016) - Aton Resources Inc. (TSX VENTURE:AAN) ("Aton" or the "Company") is pleased to announce that Mr. Rick Cavaney has been appointed Vice President, Exploration, and Mr. Javier Orduna, Head of Exploration. The appointment of Messrs. Cavaney and Orduna greatly increases the Company's geological and exploration experience and are timely additions as Aton advances Hamama West to an initial resource.

Syndicated Metals Ltd snaps up gold mine near 3.2Moz Mt Morgans

Syndicated Metals Ltd (ASX:SMD) will acquire the Monument Gold Project in Western Australia’s world‐class Laverton gold district, through the purchase of a private company. The Monument Gold Project comprises of 210 square kilometres of tenement adjacent to the 3.2 million ounces Mt Morgans Gold Project, currently being explored by Dacian Gold Ltd (ASX:DCN). Syndicated will acquire the project for $50,000 in cash and 23,767,082 Syndicated shares worth $200,000 at $0.

Carpentaria Exploration Ltd to supply iron ore to global high grade market

Carpentaria Exploration Ltd (ASX:CAP) is focused on delivering the best quality iron concentrates into the growing premium end of the iron ore market.

CAP Investor Presentation


Half-Yearly Accounts


Carpentaria Exploration one of ASX's Biggest Gainers intra-day

Carpentaria Exploration (ASX: CAP) is focused on discovering base, precious metals and bulk commodities in eastern Australia. The company currently has interests in iron ore, tin, gold, copper and coal exploration projects.

Quarterly Report


CAPunearthed Newsletter


Changes of Director Interests


Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...